Charles River Laboratories International (CRL) : 14 analysts are covering Charles River Laboratories International (CRL) and their average rating on the stock is 2, which is read as a Buy. 8 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Charles River Laboratories International (CRL) : 9 Wall Street analysts covering Charles River Laboratories International (CRL) believe that the average level the stock could reach for the short term is $89. The maximum price target given is $100 and the minimum target for short term is around $65, hence the standard deviation is calculated at $10.89.
For the current week, the company shares have a recommendation consensus of Buy. Charles River Laboratories International (NYSE:CRL): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $83.26 and $82.45 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $83.58. The buying momentum continued till the end and the stock did not give up its gains. It closed at $83.27, notching a gain of 0.17% for the day. The total traded volume was 327,036 . The stock had closed at $83.13 on the previous day.
In a related news, Wallman Richard F, director of Charles River Laboratories International Inc, unloaded 7,740 shares at an average price of $88 on July 29, 2016. The total amount of the transaction was worth $681,120, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Charles River Laboratories International, Inc. is a full service, early stage contract research company. The Company offers research models for the research and development of new drugs, devices and therapies. It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS), which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides services that enables the clients to outsource their drug discovery research, critical, regulatory-required safety assessment testing and related drug discovery and development activities, and Manufacturing Support (Manufacturing), which is involved in the production and release of products manufactured by the clients.